Alembic Pharmaceuticals has reported results for third quarter ended December 31, 2022.
The company has reported fall of 32.62% in its net profit at Rs 119.13 crore for Q3FY23 as compared to Rs 176.80 crore for the corresponding quarter previous year. However, total income of the company increased by 4.59% to Rs 1,310.80 crore for the quarter under review as compared to Rs 1,253.26 crore for the same quarter in the previous year.
On the consolidated basis, the company has reported fall of 29.03% in its net profit at Rs 121.92 crore for Q3FY23 as compared to Rs 171.79 crore for the same quarter in the previous year. However, total income of the company increased by 17.29% to Rs 1,509.46 crore for the quarter under review as compared to Rs 1,286.96 crore for the same quarter in the previous year.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1504.25 |
Dr. Reddys Lab | 6263.70 |
Cipla | 1406.25 |
Zydus Lifesciences | 948.20 |
Lupin | 1615.85 |
View more.. |